Bengay Market Positioning OK, But Several Claims Misleading – NAD
This article was originally published in The Tan Sheet
Executive Summary
Labeling claims suggesting Pfizer Consumer Healthcare's Arthritis Formula Bengay was developed expressly to relieve pain experienced by arthritis sufferers are erroneous and should be discontinued, the National Advertising Division determines
You may also be interested in...
Joint-Ritis Ranks Second Among External Analgesic Rubs – IRI Data
Naturopathic Labs has extended its Joint-Ritis advertising campaign from exclusively radio spots to include a print component
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands